AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) rose 8.1% during mid-day trading on Wednesday . The stock traded as high as $27.00 and last traded at $26.96, with a volume of 668,312 shares changing hands. The stock had previously closed at $24.95.

Several research firms have commented on AMAG. Raymond James Financial Inc. lowered shares of AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 4th. Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, April 29th. Deutsche Bank AG lowered their price objective on shares of AMAG Pharmaceuticals from $42.00 to $35.00 and set a “hold” rating for the company in a research note on Monday, May 9th. Leerink Swann reaffirmed an “outperform” rating on shares of AMAG Pharmaceuticals in a research note on Saturday, April 16th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of AMAG Pharmaceuticals in a research note on Thursday, June 2nd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $38.20.

The stock has a market capitalization of $924.96 million and a PE ratio of 89.46. The company’s 50-day moving average is $24.51 and its 200-day moving average is $23.53.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.11 by $0.17. The firm earned $117.60 million during the quarter, compared to analyst estimates of $124.83 million. During the same quarter in the prior year, the firm posted $1.17 earnings per share. The company’s revenue for the quarter was up 41.9% on a year-over-year basis. On average, analysts predict that AMAG Pharmaceuticals Inc. will post $5.20 earnings per share for the current year.

Other institutional investors have added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in shares of AMAG Pharmaceuticals by 10.1% in the fourth quarter. Rhumbline Advisers now owns 37,447 shares of the specialty pharmaceutical company’s stock valued at $1,131,000 after buying an additional 3,420 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock valued at $1,893,000 after buying an additional 3,903 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of AMAG Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 397,816 shares of the specialty pharmaceutical company’s stock valued at $12,010,000 after buying an additional 8,435 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in shares of AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock valued at $1,498,000 after buying an additional 42,208 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in shares of AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock valued at $2,287,000 after buying an additional 73,152 shares in the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.